Skip to content

US · STRO · BIOTECHNOLOGY

Sutro Biopharma, Inc. (STRO) intrinsic value and stock valuation

$8.60as of 2026-11-21 · Mkt cap 242.9M

Data updated · price as of 2026-11-21

OvervaluedIC value is 20–50% below the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Sutro Biopharma, Inc. DCF and intrinsic value

InvestorsCraft values STRO with the Chepakovich two-stage DCF model — currently rated overvalued. How the model works · Run your own DCF prefilled from STRO’s statements →

Sutro Biopharma, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology South San Francisco, CA 94080 sutrobio.com

How the business is doing

Fiscal 2016–2025, USD

Revenue
$102.5M+19.1% 5y CAGRd
20162025
Net income
-$-191.09M
20162025
Free cash flow
-$-178.93M
20162025
Total equity
-$-132.45M
20162025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2016–2025, USD
20252024202320222021
Revenue$102.5M$62M$153.7M$67.8M$61.9M
Operating income-$-104.95M-$-238.45M-$-89.28M-$-128.94M-$-98.52M
Net income-$-191.09M-$-227.46M-$-106.79M-$-119.2M-$-105.54M
EPSd-$-22.48M-$-29.62M-$-17.74M-$-23.51M-$-22.89M
Operating cash flow-$-177.23M-$-191.54M-$-111.62M$3.55M-$-81.68M
Capital expenditure-$-1.7M-$-3.1M-$-4.32M-$-7.86M-$-15.32M
Free cash flow-$-178.93M-$-194.64M-$-115.93M-$-4.31M-$-97M
Total assets$173.8M$387.2M$470.7M$406.9M$341.4M
Total debt$15.7M$23.2M$33.6M$55M$57.4M
Net debt-$-42.46M-$-167.15M-$-35.63M$7.76M$27M
Total equity-$-132.45M$44.6M$149.7M$217.1M$252.6M
Cash and short-term investments$141.4M$316.9M$375.6M$334.4M$197.9M
Income statement
20252024202320222021
Revenue$102.5M$62M$153.7M$67.8M$61.9M
Cost of revenue$7.32M$7.22M$6.82M$8.29M$9.77M
Gross profit$95.2M$54.8M$146.9M$59.5M$52.1M
Research and development expenses$166.4M$252M$180.4M$137.2M$104.4M
Selling, general and administrative expenses$41M$48.5M$62.6M$59.5M$56M
Other expenses-$-7.32M-$-7.22M-$-6.82M-$-8.29M-$-9.77M
Operating expenses$200.1M$293.3M$236.2M$188.4M$150.6M
Cost and expenses$207.4M$300.5M$243M$196.7M$160.4M
Interest income$9.25M$44.4M$14.5M$3.46M$580K
Interest expense$38.2M$31.1M$23.8M$3.35M$3.14M
Depreciation and amortization$7.32M$7.22M$6.82M$8.29M$4.84M
Ebitda-$-145.65M-$-180.45M-$-67.92M-$-105.07M-$-97.56M
Operating income-$-104.95M-$-238.45M-$-89.28M-$-128.94M-$-98.52M
Total other income/expenses, net-$-86.23M$13.4M$680K$12.2M-$-7.01M
Income before tax-$-191.18M-$-225.1M-$-88.6M-$-116.7M-$-105.54M
Income tax expense-$-90K$2.36M$18.2M$2.5M$0.00
Net income-$-191.09M-$-227.46M-$-106.79M-$-119.2M-$-105.54M
Weighted average shares outstanding$8.5M$7.68M$6.02M$5.07M$4.61M
Weighted average diluted shares outstanding$8.5M$7.68M$6.02M$5.07M$4.61M
Balance sheet
20252024202320222021
Cash and short-term investments$141.4M$316.9M$375.6M$334.4M$197.9M
Net receivables$3.98M$8.62M$36.1M$7.12M$12.5M
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$150.9M$343.3M$421.5M$353.2M$218.5M
Property, plant and equipment, net$21.6M$35.9M$44.8M$51.1M$51.6M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00-$-32.02M$68.8M
Total non-current assets$22.9M$43.9M$49.2M$53.8M$122.9M
Total assets$173.8M$387.2M$470.7M$406.9M$341.4M
Accounts payable$7.57M$10.5M$9.44M$4.8M$6.01M
Short-term debt$7.78M$7.48M$10.5M$21.7M$10.4M
Deferred revenue$10.6M$69.8M$20.7M$16.8M$5.5M
Total current liabilities$75.1M$131.9M$93.8M$66.6M$41.7M
Long-term debt$7.89M$15.7M$23.2M$33.3M$47M
Deferred revenue, non-current$221.6M$193.3M$202.5M$89.9M$0.00
Total non-current liabilities$231.2M$210.7M$227.3M$123.4M$47.1M
Capital lease obligations$15.7M$23.2M$29.6M$34.2M$32.3M
Total liabilities$306.3M$342.6M$321.1M$189.9M$88.8M
Common stock$10K$80K$60K$60K$50K
Retained earnings-$-977.96M-$-786.87M-$-559.41M-$-452.62M-$-333.41M
Accumulated other comprehensive income (loss)$20K$40K$20K-$-620K-$-310K
Total equity-$-132.45M$44.6M$149.7M$217.1M$252.6M
Total investments$83.3M$126.6M$306.4M$255.1M$236.3M
Total debt$15.7M$23.2M$33.6M$55M$57.4M
Net debt-$-42.46M-$-167.15M-$-35.63M$7.76M$27M
Cash flow statement
20252024202320222021
Net income-$-191.09M-$-227.46M-$-106.79M-$-119.2M-$-105.54M
Depreciation and amortization$7.32M$7.22M$6.82M$5.69M$4.84M
Stock-based compensation$14M$24.7M$24.9M$26.3M$23.2M
Change in working capital-$-50.4M$8.9M-$-34.38M$104.4M-$-17.62M
Accounts receivable$4.64M$27.5M-$-28.96M$5.34M-$-6.89M
Inventory$0.00$0.00$0.00$0.00-$-4.54M
Accounts payable-$-2.47M$710K$4.81M-$-1.23M$6.43M
Net cash provided by operating activities-$-177.23M-$-191.54M-$-111.62M$3.55M-$-81.68M
Investments in property, plant and equipment-$-1.7M-$-3.1M-$-4.32M-$-7.86M-$-15.32M
Acquisitions, net$0.00$0.00$0.00$28.7M$0.00
Net cash used for investing activities$45M$218.5M-$-3.92M-$-35.02M-$-97.31M
Common stock issued$380K$96.5M$12M$56.3M$0.00
Common stock repurchased$0.00$0.00$0.00$0.00-$-10K
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$40K$94.1M$137.6M$48.3M$3.26M
Net change in cash-$-132.17M$121M$22M$16.8M-$-175.74M
Cash at end of period$59M$191.2M$70.1M$48.1M$31.3M
Operating cash flow-$-177.23M-$-191.54M-$-111.62M$3.55M-$-81.68M
Capital expenditure-$-1.7M-$-3.1M-$-4.32M-$-7.86M-$-15.32M
Free cash flow-$-178.93M-$-194.64M-$-115.93M-$-4.31M-$-97M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Sutro Biopharma, Inc.

        Sutro Biopharma, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and manufacturing of innovative therapeutic products. Its primary objective is to create protein-based treatments for challenging conditions like cancer and autoimmune disorders. The company achieves this through its proprietary XpressCF+ platform, a unique technology that integrates cell-free protein synthesis with precise, site-specific drug conjugation. Currently, Sutro's pipeline features two lead antibody-drug conjugate (ADC) candidates, both undergoing Phase 1 clinical evaluation. STRO-001 targets the CD74 protein, designed for individuals with multiple myeloma and non-Hodgkin lymphoma. The second candidate, STRO-002, is engineered to bind to folate receptor-alpha, intended for the treatment of ovarian and endometrial cancers. Strategic alliances are also a key part of its strategy, including collaborations and licensing agreements. A partnership with Merck aims to advance research programs involving cytokine derivatives for both oncological and autoimmune applications. Additionally, an agreement with Celgene Corporation focuses on identifying and developing bispecific antibodies and/or ADCs specifically within the immuno-oncology domain. Founded in 2003, the company initially operated under the name Fundamental Applied Biology, Inc. Its corporate headquarters are located in South San Francisco, California.

        CEO
        Jane Chung
        Employees
        133
        Beta
        1.52

        Explore

        Frequently asked questions

        What is the intrinsic value of Sutro Biopharma, Inc. (STRO)?

        Sutro Biopharma, Inc. (STRO) is currently overvalued based on the InvestorsCraft IC model — IC value is 20–50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is STRO undervalued?

        STRO trades at a price of $8.60 (Nov 21, 2026): overvalued — IC value is 20–50% below the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.